

## WEST Search History

[Hide Items](#)[Restore](#)[Clear](#)[Cancel](#)

DATE: Thursday, July 26, 2007

<b>Hide?</b>	<b>Set Name</b>	<b>Query</b>	<b>Hit Count</b>
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>			
<input type="checkbox"/>	L16	L15 and methanone	38
<input type="checkbox"/>	L15	548/517	1008
<input type="checkbox"/>	L14	L13 and methanone	13
<input type="checkbox"/>	L13	544/111	391
<input type="checkbox"/>	L11	L10 and "3-fluorophenyl"	41
<input type="checkbox"/>	L10	L9 and methanone	203
<input type="checkbox"/>	L9	514/326	3033
<input type="checkbox"/>	L8	11 and methanone	59
<input type="checkbox"/>	L1	546/207	807

END OF SEARCH HISTORY

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 16:06:47 ON 26 JUL 2007  
FILE 'CAPLUS' ENTERED AT 16:06:47 ON 26 JUL 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.48	183.79
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56
=> file registry		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.95	184.26
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

FILE 'REGISTRY' ENTERED AT 16:07:12 ON 26 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8  
DICTIONARY FILE UPDATES: 25 JUL 2007 HIGHEST RN 943407-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Program Files\Stnexp\Queries\10730265.str

L5        STRUCTURE UPLOADED

=> d 15

L5 HAS NO ANSWERS

L5                STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 16:07:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        61 TO ITERATE

100.0% PROCESSED        61 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*  
                              BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        752 TO        1688

PROJECTED ANSWERS:            2 TO        123

L6                2 SEA SSS SAM L5

=> s 15 ful

FULL SEARCH INITIATED 16:07:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED -        1094 TO ITERATE

100.0% PROCESSED        1094 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

L7                14 SEA SSS FUL L5

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

10730265

	ENTRY	SESSION
FULL ESTIMATED COST	172.10	356.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-1.56

FILE 'CAPLUS' ENTERED AT 16:07:47 ON 26 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jul 2007 VOL 147 ISS 5  
FILE LAST UPDATED: 25 Jul 2007 (20070725/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/infopolicy.html>

=> s 17

L8 4 L7

=> d abs bib hitstr 1-4

L8 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



AB The title compds. [I; R1 = H, alkyl, cycloalkylalkyl, heterocyclalkyl, aralkyl, etc.; R2 = H, halo, CN, benzodioxolyl, etc.; X = O, S; R5-R6 = H,

alkyl] and their pharmaceutically acceptable enantiomers, diastereoisomers and salts, were prepared. Thus, tropinone and N,N-diethyl-4-benzoylbenzamide (preparation given) in THF were added to a prerefluxed mixture of  $\text{TiCl}_4$  and Zn

in THF followed by 3 h reflux to give N,N-diethyl-4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide hydrochloride. The latter at 150  $\mu\text{mole/kg}$  orally in mice gave 87% inhibition of acetylcholine bromide-induced abdominal constriction. Depending on their agonist or antagonist effect, I are analgesics, immunosuppressants, antiinflammatory agents, neurol. and psychiatric drugs, medicaments for drug and alc. abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

AN 2005:15941 CAPLUS

DN 142:113912

TI Preparation of 3-(diarylmethylene)-8-azabicyclo[3.2.1]octanes as  $\delta$ - or  $\mu$ -opioid receptor modulators

IN Coats, Steven J.; Carson, John R.; Neilson, Lou Anne; Pitis, Philip M.; Schulz, Mark J.

PA USA

SO U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 360,859, abandoned.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005004163	A1	20050106	US 2004-767712	20040129
	US 2002115662	A1	20020822	US 2001-791246	20010222
	US 6552036	B2	20030422		
	US 2003181447	A1	20030925	US 2003-360859	20030207
	AU 2006235898	A1	20061130	AU 2006-235898	20061107
PRAI	US 2000-186778P	P	20000303		
	US 2001-791246	A1	20010222		
	US 2003-360859	B2	20030207		
	AU 2001-241676	A3	20010222		
	AU 2001-41676	A	20010222		

OS MARPAT 142:113912


IT 359862-92-3P 359862-95-6P 359863-17-5P  
359863-20-0P 359863-24-4P 359863-44-8P  
359863-52-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of diarylmethyleneazabicyclooctanes as  $\delta$ - or  $\mu$ -opioid receptor modulators)


RN 359862-92-3 CAPLUS

CN Morpholine, 4-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359862-95-6 CAPLUS

CN Pyrrolidine, 1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359863-17-5 CAPLUS

CN Morpholine, 4-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359863-20-0 CAPLUS

CN Pyrrolidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 359863-24-4 CAPLUS


CN Piperidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]-2,2,6,6-tetramethyl- (9CI) (CA INDEX NAME)



RN 359863-44-8 CAPLUS

CN Piperidine, 2,6-dimethyl-1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.





RN 359863-52-8 CAPLUS

CN Piperidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



AB A series of N,N-dialkyl-4-(9-aryltropanylidene)methylbenzamides, e.g. I, was prepared. The lead compounds, II (R = H) and II (R = allyl), exhibited extremely high affinity for the  $\delta$  opioid receptor with excellent selectivity vs. the  $\mu$  opioid receptor. They were full agonists at the  $\delta$  opioid receptor, as assessed by stimulation of GTPyS binding, and displayed antinociceptive activity.

AN 2004:303271 CAPLUS

DN 141:54509

TI N,N-Dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides, potent, selective  $\delta$  opioid agonists

AU Carson, John R.; Coats, Steven J.; Codd, Ellen E.; Dax, Scott L.; Lee, Jung; Martinez, Rebecca P.; Neilson, Lou Anne; Pitis, Philip M.; Zhang, Sui-Po

CS Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, LLC, Spring House, PA, 19477-0776, USA

SO Bioorganic & Medicinal Chemistry Letters (2004), 14(9), 2109-2112  
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science B.V.

DT Journal

LA English


OS CASREACT 141:54509

IT 359862-92-3P 359862-95-6P 705279-42-1P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(N,N-Dialkyl-4-[(8-azabicyclo[3.2.1]-oct-3-ylidene)phenylmethyl]benzamides as potent and selective  $\delta$  opioid agonists)

RN 359862-92-3 CAPLUS


CN Morpholine, 4-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene)methyl]benzoyl]- (9CI) (CA INDEX NAME)





RN 359862-95-6 CAPLUS


CN Pyrrolidine, 1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 705279-42-1 CAPLUS


CN Piperidine, 2,6-dimethyl-1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]-, (2R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



I

AB Title compds. [I; R1 = H, alkyl, haloalkyl, alkenyl, alkoxyalkenyl, alkynyl, alkoxyalkynyl, cycloalkyl, (substituted) heterocyclyl, heterocyclylalkyl, aryl, aralkyl, etc.; R2, R3 = (substituted) aryl, heteroaryl; A = CX, SO2; X = O, S; Z = OR4, NR5R6; R4-R6 = H, (substituted) alkyl, alkoxyalkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.], were prepared Thus, tropinone and N,N-diethyl-4-benzoylbenzamide (preparation given) in THF were added to a prerefluxed mixture of TiCl4 and Zn in THF followed by 3 h reflux to give N,N-diethyl-4-[(8-methyl-8-azabicyclo[3.2.1]oct-3-ylidene)phenylmethyl]benzamide hydrochloride. The latter at 150 µmole/kg orally in mice gave 87% inhibition of acetylcholine bromide-induced abdominal constriction. Depending on their agonist or antagonist effect, I are analgesics, immunosuppressants, antiinflammatory agents, neurol. and psychiatric drugs, medicaments for drug and alc. abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

AN 2001:676766 CAPLUS

DN 135:242144

TI Preparation of 3-(diarylmethylene)-8-azabicyclo[3.2.1]octanes as δ- or µ-opioid receptor modulators.

IN Carson, John R.; Coats, Steven J.; Neilson, Lou Anne; Wu, Wu-Nan; Boyd, Robert E.; Pitis, Philip M.

PA Ortho-McNeil Pharmaceutical, Inc., USA

SO PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066543	A2	20010913	WO 2001-US5735	20010222
	WO 2001066543	A3	20020314		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2402039	A1	20010913	CA 2001-2402039	20010222
	BR 2001008965	A	20021126	BR 2001-8965	20010222
	EP 1263758	A2	20021211	EP 2001-912949	20010222
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2003525938	T	20030902	JP 2001-565359	20010222
	AU 2006235898	A1	20061130	AU 2006-235898	20061107
PRAI	US 2000-186778P	P	20000303		
	AU 2001-241676	A3	20010222		
	AU 2001-41676	A	20010222		
	WO 2001-US5735	W	20010222		

OS MARPAT 135:242144

IT 359862-92-3P 359862-95-6P 359862-96-7P

359863-17-5P 359863-20-0P 359863-21-1P


359863-24-4P 359863-44-8P 359863-52-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of diarylmethyleneazabicyclooctanes as  $\delta$ - or  $\mu$ -opioid  
receptor modulators)


RN 359862-92-3 CAPLUS

CN Morpholine, 4-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359862-95-6 CAPLUS

CN Pyrrolidine, 1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359862-96-7 CAPLUS

CN Piperidine, 2,6-dimethyl-1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359863-17-5 CAPLUS

CN Morpholine, 4-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359863-20-0 CAPLUS

CN Pyrrolidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 359863-21-1 CAPLUS

CN Piperidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]-2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 359863-24-4 CAPLUS


CN Piperidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]-2,2,6,6-tetramethyl- (9CI) (CA INDEX NAME)



RN 359863-44-8 CAPLUS

CN Piperidine, 2,6-dimethyl-1-[4-[phenyl[8-(2-phenylethyl)-8-azabicyclo[3.2.1]oct-3-ylidene]methyl]benzoyl]-, (2R,6S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 359863-52-8 CAPLUS

CN Piperidine, 1-[4-[[8-[2-(4-methoxyphenyl)ethyl]-8-azabicyclo[3.2.1]oct-3-ylidene]phenylmethyl]benzoyl]-2,6-dimethyl-, (2R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN  
GI



AB Compds. of general formula [I; R1 = H, linear or branched C1-6 alkyl, C1-6 alkenyl, C3-8 cycloalkyl, C3-6 cycloalkyl-C1-2 alkyl, C6-10 aryl, heteroaryl having 5 to 10 atoms selected from C, S, N, and O, C1-2 alkyl-(un)substituted C6-10 aryl, C1-2 alkyl-(un)substituted heteroaryl having 5 to 10 atoms selected from C, S, N, and O; R2, R3 = H, C1-6 alkyl; A = N and/or benzene-ring 4-carbamoylphenyl, 4-sulfamoylphenyl, acylaminophenyl, or acylphenyl wherein N and/or benzene-ring are optionally substituted; B = (un)substituted aromatic, heteroarom.,

hydroarom., or heterohydroarom. moieties having 5 to 10 atoms selected from C, S, N, and O atoms] are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compns. comprising the novel compds., their use in therapy, in particular in the management of pain and in the treatment of gastrointestinal disorders, spinal injuries, disorders of the sympathetic nervous system, and isotopically labeled I as diagnostic agents. The compds. are ligands for opioid receptor, have analgesic effect, and are useful for the treatment of various pain conditions such as chronic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain, etc. (no data). Thus, tert-Bu 4-[bromo[4-(morpholinocarbonyl)phenyl]methylene]-1-piperidinecarboxylate (preparation given) was coupled with 3-fluorophenylboronic acid in the presence of (PPh<sub>3</sub>)<sub>4</sub>Pd and Na<sub>2</sub>CO<sub>3</sub> in aqueous EtOH at 80° for 2 h under N followed by treatment with CF<sub>3</sub>CO<sub>2</sub>H and acidification with aqueous HCl to give the title compound (II.HCl).

AN 1998:479508 CAPLUS

DN 129:95406

TI Preparation of 4-[diaryl- or (arylheteroaryl)methylene]piperidine derivatives with analgesic effect

IN Delorme, Daniel; Roberts, Edward; Wei, Zhongyong

PA Astra Pharma Inc., Can.; Astra Aktiebolag (Publ)

SO PCT Int. Appl., 129 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9828275	A1	19980702	WO 1997-SE2050	19971209
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	TW 548271	B	20030821	TW 1997-86118465	19971208
	ZA 9711059	A	19980622	ZA 1997-11059	19971209
	CA 2274074	A1	19980702	CA 1997-2274074	19971209
	CA 2274074	C	20060711		
	AU 9853512	A	19980717	AU 1998-53512	19971209
	AU 737999	B2	20010906		
	EP 946511	A1	19991006	EP 1997-950538	19971209
	EP 946511	B1	20050525		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1246111	A	20000301	CN 1997-181814	19971209
	BR 9714055	A	20000509	BR 1997-14055	19971209
	HU 200000610	A2	20000928	HU 2000-610	19971209
	HU 200000610	A3	20001030		
	NZ 336029	A	20010330	NZ 1997-336029	19971209
	JP 2001507350	T	20010605	JP 1998-528669	19971209
	EE 3824	B1	20020815	EE 1999-256	19971209
	RU 2193029	C2	20021120	RU 1999-115750	19971209
	SK 283211	B6	20030304	SK 1999-762	19971209
	CN 1524852	A	20040901	CN 2004-10008236	19971209
	AT 296288	T	20050615	AT 1997-950538	19971209

PL 189196	B1	20050729	PL 1997-334374	19971209
CZ 295557	B6	20050817	CZ 1999-2199	19971209
PT 946511	T	20050930	PT 1997-950538	19971209
ES 2241060	T3	20051016	ES 1997-950538	19971209
IN 1997DE03689	A	20050311	IN 1997-DE3689	19971218
US 6187792	B1	20010213	US 1998-29633	19980305
MX 9905666	A	20000131	MX 1999-5666	19990617
NO 9903022	A	19990820	NO 1999-3022	19990618
NO 313670	B1	20021111		
HK 1022689	A1	20050923	HK 2000-101528	20000311
US 2001021715	A1	20010913	US 2001-761833	20010118
US 6455545	B2	20020924		
US 2003149023	A1	20030807	US 2002-222990	20020819
US 6693117	B2	20040217		
US 2004171612	A1	20040902	US 2003-730265	20031209
PRAI SE 1996-4785	A	19961220		
SE 1997-2535	A	19970701		
WO 1997-SE2050	W	19971209		
US 1998-29633	A1	19980305		
US 2001-761833	A1	20010118		
US 2002-222990	A1	20020819		
OS MARPAT 129:95406				
IT 209807-83-0P 209807-84-1P 209807-85-2P				
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
(preparation of [diaryl- or (arylheteroaryl)methylene]piperidine derivs. with analgesic effect)				
RN 209807-83-0	CAPLUS			
CN	Morpholine, 4-[4-[(3-fluorophenyl)-4-piperidinylidenemethyl]benzoyl]-, monohydrochloride (9CI) (CA INDEX NAME)			




● HCl

RN 209807-84-1 CAPLUS  
 CN Piperidine, 1-[4-[(3-fluorophenyl)-4-piperidinylidenemethyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 209807-85-2 CAPLUS

CN Pyrrolidine, 1-[4-[(3-fluorophenyl)-4-piperidinylidenemethyl]benzoyl]-(9CI) (CA INDEX NAME)



RE.CNT 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT